Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, broaden investor appeal, and align trading conditions with the interests of shareholders. Following the split, shares will trade on the NYSE American under the existing ticker ‘CLDI,’ with a new CUSIP number of 320703 408.

The reverse stock split will convert every 12 pre-split shares into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level. This adjustment will proportionately affect outstanding options, warrants, and equity plan shares, though it will not alter the par value or the number of authorized shares. The initiative reflects Calidi Biotherapeutics’ commitment to enhancing shareholder value and ensuring the company’s stock remains attractive to a wider range of investors.

Calidi Biotherapeutics is at the forefront of developing targeted genetic medicine delivery platforms, with a focus on immuno-oncology. The company’s innovative stem cell-based platforms are designed to carry oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors. By implementing this reverse stock split, Calidi aims to strengthen its market position and continue its mission of advancing cancer treatment through groundbreaking genetic medicine delivery technologies.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics.